# An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency

> **NCT07644832** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shanghai RAAS Blood Products Co., Ltd.** · enrollment: 76 (estimated)

## Conditions studied

- Hemophilia A
- Hemophilia B
- Factor VII Deficiency

## Interventions

- **DRUG:** SR604
- **DRUG:** SR604
- **DRUG:** SR604

## Key facts

- **NCT ID:** NCT07644832
- **Lead sponsor:** Shanghai RAAS Blood Products Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-31
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2026-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07644832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07644832, "An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07644832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*